Virus-fighting T cells for adenovirus, CMV or EBV infection after transplant or weak immunity
Tests donor-made virus-fighting T cells in transplant recipients or people with weak immunity.
Key facts
- Who runs it
- Paul Szabolcs
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- Anti-viral T-cell Therapy by Gamma Capture
- Status
- Enrolling by invitation
- Phase
- Phase 1/2
- People taking part
- 25 people, planned
- Started
- 8 Jan 2024
- Expected to end
- 1 Jun 2029
- Type of study
- Interventional
- Treatments tested
- Specific T- Lymphocytes
- Record updated
- 29 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for babies, children and adults with a long-lasting adenovirus, CMV or EBV infection that did not respond to standard treatment. They must have had a transplant, an immune system disease or immune-lowering treatment.
- Age
- From 1 month. The record gives 75 years in the criteria and 65 years in the age field.
- Sex
- Males and females can join.
- Disease stage
- Adenovirus, CMV or EBV infection or disease that persists despite standard antiviral treatment. For EBV, this can be lymphoma or post-transplant lymphoproliferative disease.
- Earlier treatment
- Must have had an allogeneic stem cell transplant, or an organ transplant, or have a primary immunodeficiency, or have had immune-lowering treatment for cancer or autoimmune disease. Standard antiviral treatment must not have worked. Steroids must be reducible to less than 1 mg/kg/day prednisone before the infusion.
- Biomarker or test result
- Adenovirus, CMV or EBV found by biopsy, culture, PCR or direct fluorescent antibody stain, or a high viral load in the blood.
Main reasons for not taking part
- Antithymocyte globulin or alemtuzumab within 28 days before the infusion, without signs of T cell survival
- Active acute graft-versus-host disease grades II-IV
- Donor lymphocyte infusion within 14 days before the infusion (a fraction of cord blood is allowed)
- Active and uncontrolled return of cancer (other than EBV-positive post-transplant lymphoproliferative disorder or lymphoma)
- Another investigational product within the last 2 weeks, or breastfeeding
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Patient, parent, or legal guardian must have given written informed consent, according to FDA guidelines. For pediatric subject who are developmentally able, assent or affirmation will be obtained, if feasible
- Male or female, 1 month through 75 years old, inclusive, at the time of informed consent
- Prior allogeneic hematopoietic stem cell transplant (bone marrow, peripheral blood stem cells, single or double cord blood), OR prior solid organ transplant (liver, kidney, lung and/or heart, intestinal, or multivisceral), OR diagnosis of primary immunodeficiency OR current/recent administration of immunosuppressive therapy for cancer or autoimmune disease
- Negative pregnancy test for females ≥10 years old or who have reached menarche, unless surgically sterilized. All females of childbearing potential and lactation must agree to use an FDA approved method of birth control for the duration of their participation
- Clinical status, at the time of consent, amendable to tapering of steroids to less than 1 mg/kg/day prednisone (or equivalent) prior to cellular infusion
- Diagnosis of Adenovirus, CMV, or EBV infection, persistent despite standard therapy
- Adenovirus Infection or Disease:
- Active adenovirus infection: (i.e. gastroenteritis, pneumonia, hemorrhagic cystitis, hepatitis, pancreatitis, meningitis) defined as the demonstration of adenovirus by biopsy specimen from affected site(s) (by culture or histology), or the detection of adenovirus by culture, PCR or direct fluorescent antibody stain in fluid in the presence of worsening or persistent clinical or imaging findings despite at least 14 days of appropriate antiviral therapy (i.e. cidofovir, brincidofovir, or other available pharmacological agents) OR
- Refractory adenoviremia: defined as DNAemia >5000 copies/mL or <1 log decrease after at least 2 weeks of appropriate antiviral therapy (i.e. cidofovir, brincidofovir, or other available pharmacological agents) OR
- Intolerance of or contraindication to antiviral medications; B.CMV Infection or Disease:
- Active CMV infection: (i.e. pneumonia, meningitis, retinitis, hepatitis, hemorrhagic cystitis, and/or gastroenteritis) defined as the demonstration of CMV by biopsy specimen from affected site(s) (by culture or histology) or the detection of CMV by culture, PCR or direct fluorescent antibody stain in fluid in the presence of worsening or persistent clinical or imaging findings despite at least 14 days of appropriate antiviral therapy (i.e. Foscarnet, ganciclovir, cidofovir, or other available pharmacological agents) OR
- Refractory CMV viremia: defined as the continued presence of DNAemia, with ≥2,000 IU/mL or <1 log decrease after at least 14 days of appropriate antiviral therapy (i.e. Foscarnet, ganciclovir, cidofovir, or other available pharmacological agents) OR
- Intolerance of or contraindication to antiviral medications
- EBV Infection or Disease:
- Biopsy proven lymphoma or posttransplant lymphoproliferative disease with EBV genomes detected in tumor cells by immunocytochemistry (i.e. EBER positive) or in situ PCR, OR
- Clinical or imaging findings consistent with EBV lymphoma and associated elevated EBV viral load in peripheral blood in a patient where biopsy is deemed too high risk, OR
- Failure of antiviral therapy, as determined by one of the two bullets below after three weeks of anti-CD20 targeted therapy such as Rituximab
- There was an increase or less than 50% response at sites of lymphoma disease or lymphoproliferation
- There was a rise or a fall of less than 50% in EBV viral load in peripheral blood of PTLD patients
Who cannot take part
- Received Antithymocyte Globulin (ATG) or Alemtuzumab within 28 days of viral-specific T cell infusion and a lack of evidence of T cell survival, defined by <10 CD3+ T cells/uL (in unique situations, plasmapheresis may be considered)
- Received an investigational product in the preceding 2 weeks (prior to infusion) that may impact Viral Specific T-cells (VST) survival
- Active and uncontrolled relapse of malignancy (other than EBV+ post-transplant lymphoproliferative disorder or lymphoma)
- Received donor lymphocyte infusion, with the exception of a fraction of an umbilical cord blood, within 14 days of viral-specific T cell infusion. Subjects receiving a fraction of an umbilical cord blood within 14 days of the viral-specific T cell infusion will not be excluded
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks to participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study
- Active acute GVHD grades II-IV
- Females of child bearing potential must not be lactating
Where in United States
- UPMC Children's Hospital of PittsburghPittsburgh, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥1/6 Human Leukocyte Antigens (HLA) -matched, viral specific T cells have efficacy against adenovirus, Cytomegalovirus (CMV), and Epstein Barr Virus (EBV) in subjects who have previously received any type of allogeneic Hematopoietic Cell transplant (HCT) or solid organ transplant (SOT) or have compromised immunity. Reconstitution of anti-viral immunity by donor-derived cytotoxic T lymphocytes has shown promise in preventing and treating infections with adenovirus, CMV, and EBV. However, the weeks taken to prepare patient-specific products, and cost associated with products that may not be used limits their value. This trial will evaluate viral specific T cells generated by gamma capture technology. Eligible patients will include HCT and/or SOT recipients, and/or patients with compromised immunity who have adenovirus, CMV, or EBV infection or refractory viremia that is persistent despite standard therapy. Infusion of the cellular product will be assessed for safety and efficacy.
The group in the trial
- Viral Specific T-LymphocytesTreatment being tested
Viral Specific T-Lymphocytes Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method, viral specific, gamma-secreting T cells, are captured in a closed, sterile system.
Treatment: Specific T- Lymphocytes
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Anti-viral T-cell Therapy by Gamma Capture for High-risk Patients With Acquired or Inherited Immune Defects
- Plain-language title
- Virus-fighting T cells for adenovirus, CMV or EBV infection after transplant or weak immunityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 June 2026